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Human papillomavirus infection in Rwanda
at the moment of implementation of a
national HPV vaccination programme
Fidele Ngabo1,2, Silvia Franceschi3, Iacopo Baussano3, M. Chantal Umulisa1, Peter J. F. Snijders4,
Anne M. Uyterlinde4, Fulvio Lazzarato3,5, Vanessa Tenet3, Maurice Gatera1, Agnes Binagwaho1,6,7
and Gary M. Clifford3*
Abstract
Background: Cervical cancer is the most common female cancer in Rwanda that, in 2011, became the first African
country to implement a national vaccination programme against human papillomavirus (HPV).
Methods: To provide a robust baseline for future evaluations of vaccine effectiveness, cervical cell specimens were
obtained from 2508 women aged 18–69 years from the general population in Kigali, Rwanda, during 2013/14. 20 % of
women were HIV-positive. Samples were used for liquid-based cytology and HPV testing (44 types) with GP5+/6+ PCR.
Results: HPV prevalence was 34 %, being highest (54 %) in women ≤19 years and decreasing to 20 % at age ≥50.
Prevalence of high risk (HR) HPV and cytological abnormalities was 22 and 11 % respectively (including 2 % with
high-grade squamous intraepithelial lesions, HSIL) decreasing with age. Age-standardised prevalence of HR HPV was 22 %
(or 19 % among HIV-negative women), and HPV16 was the most common type. Prevalence of HPV and cytological
abnormalities were significantly higher in HIV-positive than HIV-negative women, and the difference increased with age.
Other significant risk factors for HPV positivity in multivariate analyses were high lifetime number of sexual partners,
receiving cash for sex, and being a farmer. 40 % of women with HSIL were infected with HPV16/18 and there was no
significant difference between HIV-positive and HIV-negative women.
Conclusions: This study confirms Rwanda to be a setting of high prevalence of HPV and cervical disease that is
worsened by HIV. These data will serve as a robust baseline for future evaluations of HPV vaccine programme
effectiveness.
Keywords: Human papillomavirus, Human immunodeficiency virus, Prevalence, Cervical cancer, Rwanda
Background
Cervical cancer represents by far the most common cancer
among females in Rwanda, and has a high age-standardised
incidence rate of approximately 42 cases per 100,000
women per year [1] that is typical of many sub-Saharan
African countries. In response to this high burden, Rwanda
became the first African country to initiate a national
vaccination programme against human papillomavirus
(HPV), the necessary cause of cervical cancer. In 2011, over
92,000 girls in primary school grade six (approximately
12 years old) were vaccinated with quadrivalent (HPV16/
18/6/11) HPV vaccine. The three-dose vaccination coverage
was estimated at 93 % in the target population [2]. During
2012 and 2013, a catch-up vaccination targeted girls also in
secondary school grade three (approximately 15 years old)
whereas from 2014, vaccination has reverted to targeting
primary school grade six only.
However, the impact of HPV vaccination on cervical
cancer will likely not be observed for 20 years at least, so
earlier evidence of vaccine programme effectiveness is
important to encourage planners in Rwanda and other
African countries to sustain their programmes. To this
end, the Rwandan Ministry of Health, in collaboration
with the International Agency for Research on Cancer
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(IARC), initiated a series of studies to evaluate the early
impact of HPV vaccination on HPV prevalence.
A pre-vaccination study of the prevalence of, and risk
factors for, HPV infection, was initiated in 2011 according
to the standard protocol of the IARC HPV prevalence
surveys [3]. Cervicovaginal samples were collected from
women aged 18–69 years living in the capital, Kigali, with
a particular effort to oversample women ≤25 years of age
in whom the impact of vaccination on HPV prevalence
should be seen the earliest. The influence of HIV positiv-
ity, which is known to be an important determinant of
HPV prevalence and may affect the future effectiveness of
HPV vaccination, was also evaluated.
Methods
Population
Between July 2013 and May 2014, a survey was con-
ducted by the Ministry of Health of Rwanda in collabor-
ation with the IARC, Lyon, France. The study aim was
to enrol 2500 women from the general population using
an age-stratified approach, namely 1000 women aged
below 25 years old, 500 women aged 25 to 29 years old,
200 women in each 5-year age group between 30–34
and 45–49 years, and 200 women aged ≥50 years. All
mentally and physically competent women were eligible
for the study, regardless of their marital status, with
exception of those who were known to be pregnant.
All participants were residents of Nyarugenge District,
Kigali and were recruited in two ways: 1) A population-
based invitation of women aged 18–69 years residing in
pre-defined areas of Nyarugenge District was made
through community workers and community meetings.
Women were invited to attend the Reproductive Health
Department of the district hospital (Muhima). Participation
rates are difficult to estimate due to the uncertainty on the
number of women who had been reached by the informa-
tion campaign. 2) An additional opportunistic approach
was used to recruit women aged ≤29 years who were spon-
taneously attending Muhima hospital or eight other health
centers in the Nyarugenge District (Muhima, Butamwa,
Rugarama, Mwendo, Corum, Gitega, Kabusunzu, Biryogo).
Principal reasons for consultation were family planning,
childhood vaccination, post-natal care services and HIV-
related services. Study procedures were undertaken in the
centre where the woman was consulting and very few
refusals were recorded.
Following signature of an informed consent form, a
structured risk questionnaire was administered to all study
participants, and data transferred electronically to IARC
via a specifically designed on-line webpage/application.
A cytobrush (Cervex-Brush, Rovers Medical Devices
B.V., The Netherlands) was used for the collection of
exfoliated cervical cells from the endocervix and ectocer-
vix for all women. The brush containing cellular material
was placed in a vial containing PreservCyt medium
(Cytyc, Boxbourough, MA, USA) and stored at +4C
until shipment.
Women aged ≥30 years old also underwent screen-
ing by visual inspection with acetic acid (VIA).
Women with visible abnormalities of the cervix, and/
or who were positive for high risk (HR) HPV infec-
tion (for which results became available at a later
date, see below) were to be recalled for a second VIA
and treatment according to national protocols (includ-
ing cryotherapy, thermo coagulation or loop electro-
surgical excision of the cervix transition zone).
Biopsies were to be taken from all HPV-positive
women, either VIA-directed to a visible lesion or ran-
domly from 12 o’clock of the transformation zone in
the absence of a visible lesion, prior to any treatment.
Histological confirmation of cervical tissue was per-
formed at the Department of Pathology at the Kigali
Teaching University Hospital. Histology results are
the subject of ongoing quality control and, apart from
invasive cervical cancer, are not reported here.
Among women ≤29 years, no VIA was performed,
nor were HR HPV-positive women recalled for
follow-up.
HPV testing and liquid based cytology (LBC)
HPV testing was performed on exfoliated cervical
cells in the Department of Pathology at the VU Uni-
versity Medical Center, Amsterdam. DNA was
extracted from the PreservCyt sample using mag-
netic beads (Macherey-Nagel) on a robotic system
(Hamilton Robotics) according to the manufacturer’s
instructions. Beta-Globin PCR analysis was con-
ducted first to confirm the presence of human DNA
in all specimens [4]. The presence of HPV DNA was
determined by conducting a general primer GP5+/6+ −
mediated PCR, which permits the detection of a broad
spectrum of genital HPV types [5]. HPV positivity was
assessed by hybridization of PCR products in an enzyme
immunoassay with two oligoprobe cocktails that, together,
detect 44 mucosal HPV types. Subsequent HPV genotyp-
ing was conducted by reverse-line blot hybridization of
GP5+/6+ PCR products [6]. HPV types considered HR
types for this analysis were HPV16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68 [7]; possible HR types HPV26,
30, 34, 53, 66, 67, 69, 70, 73, 82, and 85; low-risk (LR)
types HPV6, 11, 32, 40, 42, 43, 44, 54, 55, 57, 61, 64, 71,
72, 81, 83, 84, 86, 89, and 90.
Liquid-based cytology slides were prepared using a
Thin Prep 3000 processor (Cytyc-Hologic), and were
read at the Department of Pathology at the Vrije Uni-
versity Medical Center, Amsterdam, The Netherlands.
Cytological diagnoses were reported according to
CISOE-A standards [8] and were translated into
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Bethesda 2001 terminology system as 1) normal, 2)
atypical squamous cells of undetermined significance;
atypical squamous cells cannot exclude high-grade
lesion; atypical glandular cells of undetermined
significance; low-grade squamous intraepithelial
lesions (ASCUS/ASC-H/AGUS/LSIL), 3) high-grade
squamous intraepithelial lesions (HSIL), or 4) invasive
cancer.
Statistical analyses
Age-standardised HPV prevalence was computed using
the world standardised population to allow comparisons
of HPV prevalence with other IARC HPV surveys [9]. Ad-
justed prevalence ratios (PR) for HPV positivity and corre-
sponding 95 % confidence intervals (CI) were computed
using two binomial regression models with a log link, the
first adjusted for age group (<24; 25–34, 35–44 and
≥45 years) only, and a second model that adjusted add-
itionally for lifetime sexual partners (1, 2 or ≥3) and HIV
status (positive, negative, unknown). Risk trends were
assessed by considering categories as continuous variables.
Effect modification of HIV status on the association be-
tween HPV16/18 positivity and cytology was tested using
the log-likelihood ratio test.
Results
General female population
Of 2511 participants providing cervical cell samples,
2508 had valid HPV results and were included in the fol-
lowing analyses, including 1233 and 1275 recruited at
Muhima Hospital and health centres, respectively.
Ninety nine percent of women reported no HPV vaccin-
ation and 98 % no history of previous cervical cancer
screening. Among the 2391 women with a valid result
on LBC, 255 (11 %) had an abnormal cytological diagno-
sis, including 210 (9 %) with ASCUS/ASC-H/AGUS/
LSIL and 45 (2 %) with HSIL.
Overall HPV prevalence was 34 %, being 29 % among
women with normal cytology (Table 1). The prevalence
of HPV was 73 and 96 % in ASCUS/ASC-H/AGUS/LSIL
and HSIL, respectively. In total, 480 (19 %) women had
single-type and 377 (15 %) had multiple-type infections.
Crude and age-standardised prevalence of HR HPV
types was 22 %. Prevalence of possible HR HPV and LR
HPV was 10 and 15 % respectively. HPV16 was the most
common HPV type in women with normal cytology
(4 %), ASCUS/ASC-H/AGUS/LSIL (11 %), and HSIL
(29 %). HPV52 and HPV35 were the next most common
HR types in women with normal cytology and ASCUS/
ASC-H/AGUS/LSIL, compared to HPV18 and HPV58
in HSIL. Four invasive cervical cancers were found in
the study population (2 HPV16, 1 HPV33, 1 HPV nega-
tive), and two additional invasive cervical cancers among
participants without a valid sample for HPV and
cytology.
Figure 1 shows the age-specific prevalence of HPV and
cytological abnormalities, with HPV-positive women
classified hierarchically into (1) HPV16 and/or 18, (2)
other HR types and (3) LR types only. Overall HPV
prevalence was highest (54 %) among women ≤19 years,
and decreased with age, down to 20 % among women
aged ≥50 years. Prevalence of cytological abnormalities
showed no clear trend by age group.
A total of 490 (20 %) study participants self-reported
to be HIV-positive, and 1414 (56 %) to be HIV-negative.
An additional 604 (24 %) who reported not to know
their HIV-status are hereafter considered as HIV-
negative, based on similar risk factor profiles and sensi-
tivity analyses after the exclusion of women with un-
known HIV status. Eighty-four percent of HIV-positive
women were receiving combined anti-retroviral therapy
(cART) (data not shown). Of note, HIV-positive women
represented 11 % of the study population below age 25
but 34 % in those age 45 or older.
Table 2 shows the relationship between HPV positivity
and selected women’s characteristics. In the age-adjusted
model, variables significantly associated with HPV posi-
tivity were age group, occupation, tobacco use, marital
status, number of lifetime sexual partners, history of re-
ceiving cash for sex, the presence of anogenital warts,
HIV positivity, number of pregnancies and contraceptive
use in the last year. Additional adjustment for the two
strongest risk factors, lifetime number of sexual partners
and HIV, attenuated most PRs for HPV positivity, and
the remaining significant associations included age
group (PR for ≥45 vs ≤24 years = 0.45; 95 % CI: 0.37–
0.55), marital status (PR for single versus married = 1.16;
95 % CI: 1.02–1.30), being a farmer (PR for farmers ver-
sus housewives = 0.78; 95 % CI: 0.66–0.92), number of
lifetime sexual partners (PR for ≥3 vs 1 = 1.53; 95 % CI:
1.33–1.77), HIV positivity (PR = 1.54; 95 % CI: 1.36–
1.75), number of pregnancies (PR for ≥4 vs 1 = 0.78;
95 % CI: 0.63–0.97), and use of contraceptive methods
in the last year (PR for any = 0.82; 95 % CI: 0.74–0.91).
Among contraceptive methods, condom did not reach
statistical significance in multi-variate analysis. No sig-
nificant associations with HPV positivity were seen for
body mass index (5 % underweight, 7 % obese), age at
menarche (median = 14 years), age at first sexual inter-
course (median = 18 years), nor difference in age with
partner at first sexual intercourse (median = 5 years
younger) (data not shown).
In addition to total HPV prevalence, HR HPV preva-
lence was also significantly higher among HIV-positive
(32 %) than in HIV-negative (20 %) women. Figure 2
shows prevalence of HR HPV infection, and of cyto-
logical abnormalities among HR HPV-positive women,
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stratified by age group and HIV positivity. PRs for HR
HPV prevalence by HIV-positivity increased with in-
creasing age from 1.6 (95 % CI: 1.3–2.0) in women
below age 25 up to 4.0 (95 % CI: 2.3–7.0) in women aged
45 or older (Fig. 2). The percentage of HR HPV-positive
that had cytological abnormalities was significantly
higher in HIV-positive than HIV-negative women below
age 25 (PR = 1.7, 95 % CI: 1.2–2.6) but similar in older
age groups.
The proportion of women who were positive for
HPV16/18 is shown in Table 3, by cytological diagnosis
and HIV status. Overall, the proportion of HPV16/18-
positive women increased from 5.5 % in normal cytology
up to 40 % in HSIL with no statistically significant
Table 1 Prevalence of human papillomavirus (HPV) types by cytological findings and overall, among 2508 women. Rwanda, 2013–2014
HPV type Normal (N = 2136) ASCUS/ASC-H/LSIL (n = 210) HSIL (n = 45) Total (n = 2508) a
N % N % N % N %
Negative 1510 70.7 56 26.7 2 4.4 1651 65.8
Positive 626 29.3 154 73.3 43 95.6 857 34.2
Multiple 250 11.7 85 40.5 23 51.1 377 15.0
High-risk
16 88 4.1 23 11.0 13 28.9 131 5.2
18 31 1.5 13 6.2 6 13.3 52 2.1
31 35 1.6 12 5.7 4 8.9 54 2.2
33 29 1.4 4 1.9 3 6.7 36 1.4
35 48 2.2 20 9.5 4 8.9 75 3.0
39 22 1.0 10 4.8 2 4.4 37 1.5
45 36 1.7 12 5.7 4 8.9 55 2.2
51 29 1.4 14 6.7 2 4.4 47 1.9
52 50 2.3 20 9.5 3 6.7 76 3.0
56 38 1.8 13 6.2 4 8.9 59 2.4
58 38 1.8 17 8.1 9 20.0 68 2.7
59 28 1.3 6 2.9 0 0.0 36 1.4
68 11 0.5 2 1.0 2 4.4 16 0.6
Any 378 17.7 113 53.8 40 88.9 557 22.2
Possibly high-risk
26 9 0.4 4 1.9 3 6.7 16 0.6
30 11 0.5 6 2.9 1 2.2 18 0.7
34 0 0.0 1 0.5 0 0.0 1 0.0
53 13 0.6 11 5.2 2 4.4 26 1.0
66 39 1.8 18 8.6 1 2.2 63 2.5
67 53 2.5 8 3.8 5 11.1 68 2.7
69 11 0.5 5 2.4 0 0.0 17 0.7
70 30 1.4 8 3.8 0 0.0 38 1.5
73 13 0.6 2 1.0 1 2.2 19 0.8
82 11 0.5 6 2.9 0 0.0 18 0.7
85 4 0.2 1 0.5 1 2.2 6 0.2
Any 167 7.8 60 28.6 10 22.2 248 9.9
Low risk
6 28 1.3 10 4.8 0 0.0 40 1.6
11 15 0.7 4 1.9 0 0.0 20 0.8
Any 282 13.2 59 28.1 10 22.2 368 14.7
aIncluding 117 women with missing/inadequate cytology
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heterogeneity by HIV status (p for heterogeneity = 0.33)
(Table 3).
Of 976 women that underwent VIA, only 5 % were
classified as positive and only one of the 22 HSILs de-
tected in this group of women was VIA-positive (data
not shown).
Discussion
We describe the epidemiology of HPV infection in the
adult female population of Rwanda soon after the coun-
try successfully embarked upon a national programme of
HPV vaccination. Data represent that of an almost en-
tirely vaccine- and screening-naive population and dis-
close a high prevalence of HPV infection (34 %),
particularly among women ≤19 years (54 %). Findings
can be robustly compared with other IARC HPV surveys
that were conducted according to a similar protocol. In
this respect, the age-standardised HR HPV prevalence of
22 % in Rwanda (or 19 % in HIV-negative women) ranks
below that of Guinea (31 %) [10] and Mongolia (25 %)
[11], is similar to the prevalence detected in Nigeria
(18 %) [12] and Vanuatu (19 %) [13], but remains more
elevated than that found in many other areas known to
be at high-risk for cervical cancer, including that in India
(12 %) [14] and Colombia (10 %) [15]. The high preva-
lence of HSIL and cervical cancer in the study popula-
tion is consistent with recent estimates of high cervical
cancer incidence in Rwanda [1].
HPV16 was by far the most frequently detected type
in Rwanda, increasing from 4 % of normal cytology up
to 29 % of HSIL. This agrees with a meta-analysis in
which the proportion of HPV16-positive HSIL in Africa
was 30 %, and lower than in other world regions [16].
Vaccine types HPV16 and/or 18 accounting for 42 % of
HSIL, and a relatively high importance of HPV35 and
HPV58 in Rwanda are also consistent with previous
African studies [16]. The importance of HPV16 and 18
increased with the severity of cytological lesions similarly
in HIV-negative and HIV-positive, and we did not ob-
serve any statistically significant under-representation of
HPV16/18 in HIV-positive HSIL, as has been suggested
by meta-analyses [17].
HIV infection was associated with higher prevalence of
HPV, confirming previous findings from Rwanda [18–20];
sub-Saharan Africa [21–25] and elsewhere [17]. This asso-
ciation persisted after adjustment for lifetime number of
sexual partners, confirming an independent effect of HIV-
infection beyond that of confounding by sexual behaviour.
Indeed, lower CD4+ cell counts (a specific measure of
HIV-related immunosuppression) are known to be nega-
tively associated with the prevalence [26–29], persistence
[30], and cumulative incidence [31] of HPV infection.
In agreement with our present findings, some studies
in sub-Saharan African populations have reported de-
clining HPV prevalence with age [21, 32–34], whereas
others have showed HPV prevalence remaining equally
high [10, 12, 35–37], or even increasing [38] in middle
and old age. Even if it declined, HR HPV prevalence
remained 10–15 % in women age 35 or older in Rwanda,
suggesting that a large proportion of women might test
positive for HPV-based screening and require diagnostic
follow-up and treatment. This problem particularly ap-
plies to HIV-positive women, among whom HR HPV
prevalence decreased less with age than among HIV-
negative women.
Risk factors, other than HIV and age group, associated
with cervical HPV infection were mostly proxies of sex-
ual behaviour, as identified in previous HPV prevalence
Fig. 1 Age-specific prevalence of human papillomavirus (HPV) DNA and of cytological abnormalities among 2508 women. Rwanda, 2013–2014
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Table 2 Prevalence ratios (PR) for human papillomavirus (HPV) positivity and corresponding 95 % confidence intervals (CIs)
according to selected characteristics among 2508 women. Rwanda, 2013–2014
Characteristic N women a HPV-positive (%) Adjusted b PR 95 % CI Adjusted c PR 95 % CI
Age-group (years)
≤ 24 1179 500 (42.4) 1 - 1 -
25–34 519 170 (32.8) 0.77 0.67–0.89 0.71 0.62–0.82
35–44 406 101 (24.9) 0.59 0.49–0.70 0.52 0.44–0.63
≥ 45 404 86 (21.3) 0.50 0.41–0.61 0.45 0.37–0.55
Chi2(1) for trend p <0.001 p <0.001
Education (Years)
Non-literate 0–5 325 122 (37.5) 1 - 1 -
Literate 0–5 640 226 (35.3) 0.86 0.73–1.03 0.97 0.82–1.14
Literate 6–10 1123 383 (34.1) 0.88 0.75–1.03 1.00 0.86–1.17
Literate ≥11 420 126 (30.0) 0.85 0.70–1.04 0.99 0.82–1.20
Chi2(1) for trend p =0.199 p =0.849
Occupation
Housewife 964 366 (38.0) 1 - 1 -
Shopkeeper/salesman 391 154 (39.4) 1.13 0.98–1.31 1.03 0.90–1.18
Manual worker 400 132 (33.0) 0.90 0.77–1.06 0.92 0.79–1.08
Teacher/health worker/Student/Clerical staff 188 56 (29.8) 0.93 0.73–1.17 0.92 0.73–1.15
Farmer 532 134 (25.2) 0.72 0.61–0.85 0.78 0.66–0.92
Tobacco use
Never 2276 766 (33.7) 1 - 1 -
Ever 230 91 (39.6) 1.45 1.23–1.71 1.13 0.96–1.32
Marital status
Married or cohabiting 1734 533 (30.7) 1 - 1 -
Single 444 212 (47.8) 1.35 1.20–1.53 1.16 1.02–1.30
Separated/widowed 330 112 (33.9) 1.38 1.17–1.63 1.16 0.98–1.37
Lifetime sexual partnersd
1 1131 294 (26.0) 1 - 1 -
2 701 263 (37.5) 1.45 1.26–1.65 1.37 1.20–1.56
3 281 128 (45.6)
} 1.84e 1.62–2.10 1.53e 1.33–1.77
≥ 4 248 116 (46.8)
Chi2(1) for trend p <0.001 p <0.001
Sexual activity in the last year
Yes 2189 766 (35.0) 1 - 1 -
No 299 84 (28.1) 1.07 0.87–1.30 0.93 0.77–1.14
History of receiving cash for sexd
Never 2333 769 (33.0) 1 - 1 -
Ever 154 85 (55.2) 1.59 1.37–1.84 1.14 0.98–1.33
Evidence of anogenital warts
No 2395 814 (34.0) 1 - 1 -
Yes 113 43 (38.1) 1.35 1.07–1.72 1.09 0.88–1.35
HIV status
Negative 1414 450 (31.8) 1 - 1 -
Unknown 604 166 (27.5) 1.01 0.87–1.18 1.02 0.87–1.18
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surveys. Lifetime number of sexual partners, being
single, and history of receiving cash for sex (albeit
rarely reported), were positively associated with HPV
prevalence in multivariate analyses. Multiparity and
recent use of contraceptives were also significantly
and negatively associated with HPV positivity. Lower
prevalence in farmers than other occupational groups
suggest the possibility of an urban–rural gradient in
the frequency of the infection. Residual confounding
by sexual behaviour on the association with occupa-
tion, multiparity, and contraceptive use is difficult to
rule out [39, 40].
Fig. 2 Age-specific prevalence of HR HPV infection, and of cytological abnormalities among HR HPV-positive women, stratified by HIV status among
2508 women. Rwanda, 2013–2014
Table 2 Prevalence ratios (PR) for human papillomavirus (HPV) positivity and corresponding 95 % confidence intervals (CIs)
according to selected characteristics among 2508 women. Rwanda, 2013–2014 (Continued)
Positive 490 241 (49.2) 1.84 1.65–2.06 1.54 1.36–1.75
Number of pregnancies
Nulliparous 237 101 (42.6) 1.15 0.97–1.36 0.99 0.85–1.15
1 804 327 (40.7) 1 - 1 -
2-3 840 285 (33.9) 0.94 0.83–1.08 0.85 0.75–0.97
≥ 4 616 141 (22.9) 0.85 0.67–1.06 0.78 0.63–0.97
Chi2(1) for trend p =0.010 p =0.006
Contraceptive use in the last year
No 1146 422 (36.8) 1 - 1 -
Yes 1359 432 (31.8) 0.80 0.72–0.89 0.82 0.74–0.91
Hormonal 1005 339 (33.7) 0.82 0.73–0.92 0.84 0.75–0.96
Intra Uterine Device 185 54 (29.2) 0.79 0.62–1.00 0.79 0.62–1.00
Condom 72 25 (34.7) 0.92 0.67–1.27 0.86 0.64–1.16
Other/two or more of above 97 14 (14.4) 0.48 0.29–0.78 0.45 0.26–0.78
aSome figures do not add up to the total due to missing values
bAdjusted for age as appropriate
cAdjusted for age, HIV status and lifetime sexual partners as appropriate
dthree virgins excluded
ePR ratio is calculated for “three lifetime sexual partners or more”
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Although only 2 % of study participants reported a prior
Pap smear, the current study coincided with the initiation
of screening and treatment programmes based on VIA,
and/or testing for HPV DNA with careHPV (QIAGEN,
Hilden, Germany) with use of VIA to triage HPV-positives
for treatment [41]. A potential warning about the per-
formance of VIA in this setting comes from the finding
that, despite very high HR HPV prevalence, VIA detected
abnormalities in only 5 % of women in this high-risk
population, and missed the vast majority of HSIL. This
mirrors findings from other IARC HPV surveys [10, 42].
This study has strengths and weaknesses. Strengths in-
clude the relatively large number of women, especially
young women, and the use of high-quality HPV testing
and liquid-based cytology. HPV infection is asymptomatic
and self-selection of women by level of HPV risk is un-
likely to have occurred. The large number of HIV-positive
women in our study will allow the opportunity to estimate
HPV vaccine effectiveness in this high-risk group separ-
ately but also raises the question of whether our study
population is representative of the general female popula-
tion in Kigali, and Rwanda as a whole. HIV-positive
women are over-represented in our survey in comparison
to the general population [43]. In particular, HIV-positive
women (in the vast majority under cART treatment) were
clearly more willing to accept screening invitations, or to
be spontaneously seeking medical care, than HIV-negative
women and represented approximately one third of study
women age 35 or older. Had overall age-standardised HR
HPV prevalence been estimated among HIV-negative
women only, however, findings would have not been very
different: 19 % instead of 22 %.
Conclusions
The findings of this study confirm Rwanda to be a setting
of high prevalence of HPV and cervical disease that is
worsened by HIV co-infection. These data will serve as a
robust baseline for evaluations of HPV vaccine programme
effectiveness in future cohorts of vaccinated girls.
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